Management of respiratory syncytial virus infection

Current Opinion in Infectious Diseases

Volumn 14, Issue 3, 2001, Pages 323-328

  Kimpen, J L L ^a  

^a NONE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BRONCHODILATING AGENT; CORTICOSTEROID; HUMAN MONOCLONAL ANTIBODY; IMMUNOGLOBULIN; PALIVIZUMAB; RIBAVIRIN;

BRONCHIOLITIS; DRUG COST; DRUG EFFICACY; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; LOWER RESPIRATORY TRACT INFECTION; PROPHYLAXIS; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVIEW; VIRUS INFECTION;

EID: 0035010120     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001432-200106000-00013     Document Type: Review

References (48)

1. Prophylaxis against respiratory syncytial virus in premature infants
2. Novel pathways in the pathogenesis of respiratory syncytial virus disease
3. Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years
4. Respiratory syncytial virus bronchiolitis in infancy is an important risk factor for asthma and allergy at age 7
5. Respiratory syncytial virus infection
6. Respiratory syncytial virus
7. Nosocomial respiratory syncytial virus infections: The cost-effectiveness and cost-benefit of infection control
8. Hyperimmune globulins in prevention and treatment of respiratory syncytial virus infections
9. Controlled trial to evaluate protection of high-risk infants against respiratory syncytial virus disease by using standard intravenous immune globulin
10. Comparison of antibody concentrations and protective activity of respiratory syncytial virus immune globulin and conventional immune globulin
11. Safety and bioequivalency of three formulations of respiratory syncytial virus-enriched immunoglobulin
12. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children
13. Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis
14. Respiratory syncytial virus immune globulin for prophylaxis against respiratory syncytial virus disease in infants and children with congenital heart disease
15. Immunoglobulin for preventing respiratory syncytial virus infection (Cochrane Review)
16. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody reduces hospitalization from respiratory syncytial virus infection in high-risk infants
17. Prevention of respiratory syncytial virus infections: Indications for the use of palivizumab and update on the use of RSV-IGIV
18. A number-needed-to-treat analysis of the use of respiratory syncytial virus immune globulin to prevent hospitalization
19. Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants
20. Prophylaxis for respiratory syncytial virus with respiratory syncytial virus-immunoglobulin intravenous among preterm infants of thirty-two weeks gestation and less: Reduction in incidence, severity of illness and cost
21. Hospitalisation for RSV infection in ex-preterm infants implications for use of RSV immune globulin
22. Respiratory syncytial virus infection in high risk infants and the potential impact of prophylaxis in a United Kingdom cohort
23. Respiratory syncytial virus and premature infants born at 32 weeks' gestation or earlier: Hospitalization and economic implications of prophylaxis
24. Ribavirin for respiratory syncytial virus lower respiratory tract infection. A systematic overview
25. Ribavirin for respiratory syncytial virus infection of the lower respiratory tract (Cochrane Review)
26. A controlled trial of aerosolized ribavirin in infants receiving mechanical ventilation for severe respiratory syncytial virus infection
27. Aerosolized ribavirin in mechanically ventilated children with respiratory syncytial virus lower respiratory tract disease: A prospective, double-blind, randomized trial
28. Ribavirin in ventilated respiratory syncytial virus bronchiolitis. A randomized, placebo-controlled trial
29. Respiratory syncytial virus upper respiratory tract illnesses in adult blood and marrow transplant recipients: Combination therapy with aerosolized ribavirin and intravenous immunoglobulin
30. Efficacy of β2-agonists in bronchiolitis: A reappraisal and meta-analysis
31. Efficacy of bronchodilator therapy in bronchiolitis. A meta-analysis
32. Bronchodilators for bronchiolitis (Cochrane Review)
33. Inhaled nebulized adrenaline improves lung function in infants with acute bronchiolitis
34. Therapy for respiratory tract infections caused by respiratory syncytial virus
35. Treatment and prevention of respiratory syncytial virus infection
36. Systemic corticosteroids in infant bronchiolitis: A meta-analysis
37. Randomised double blind placebo controlled trial of prednisolone in children admitted to hospital with respiratory syncytial virus bronchiolitis
38. Prednisolone treatment of respiratory syncytial virus infection: A randomized controlled trial of 147 infants
39. Prednisolone plus albuterol versus albuterol alone in mild to moderate bronchiolitis
40. Randomised placebo controlled trial of nebulised corticosteroids in acute respiratory syncytial viral bronchiolitis
41. Long-term effects of prednisolone in the acute phase of bronchiolitis caused by respiratory syncytial virus
42. Inhaled corticosteroids during and after respiratory syncytial virus-bronchiolitis may decrease subsequent asthma
43. Nebulised beclomethasone dipropionate in recurrent obstructive episodes after acute bronchiolitis
44. Treatment of respiratory syncytial virus bronchiolitis: 1995 Poll of members of the european society for paediatric infectious diseases
45. Differences in management of bronchiolitis between hospitals in The Netherlands
46. Standardizing the care of bronchiolitis
47. Evaluation of an evidence-based guideline for bronchiolitis
48. Sustaining the implementation of an evidence-based guideline for bronchiolitis